TPO

Across TCGA pan-cancer cohorts, TPO Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated TPO data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher TPO Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TPO expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, UCS, and HNSC are the cancer types where TPO Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCS	OS	Median	All	0.102	0.688	<.001	36	view →
HNSC	OS	Median	All	0.204	0.714	<.001	24	view →
BLCA	OS	Median	III,IV	0.211	0.689	<.001	13	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
PRAD	DFS	Median	All	0.617	0.886	.011	6	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
ESCA	OS	Median	II,III,IV	0.406	0.925	.021	3	view →
UCEC	DFS	Median	All	0.879	0.616	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

TPO–THYM (OS)

Open the THYM breakdown →